A 0 1 0 1 O
castrate 2 10 2 10 B-clinical_variable
level 11 16 11 16 I-clinical_variable
of 17 19 17 19 I-clinical_variable
testosterone 20 32 20 32 I-clinical_variable
( 33 34 33 34 O
< 34 35 34 35 O
50ng 36 40 36 40 B-upper_bound
/ 40 41 40 41 I-upper_bound
dL 41 43 41 43 I-upper_bound
) 43 44 43 44 O

AST 0 3 45 48 B-clinical_variable
and 4 7 49 52 O
ALT 8 11 53 56 B-clinical_variable
< 12 13 57 58 O
2.5 14 17 59 62 B-upper_bound
x 18 19 63 64 I-upper_bound
ULN 20 23 65 68 I-upper_bound

Absolute 0 8 69 77 B-clinical_variable
neutrophil 9 19 78 88 I-clinical_variable
count 20 25 89 94 I-clinical_variable
( 26 27 95 96 I-clinical_variable
ANC 27 30 96 99 I-clinical_variable
) 30 31 99 100 I-clinical_variable
≥ 32 33 101 102 O
1500/µL 34 41 103 110 B-lower_bound

Active 0 6 111 117 B-chronic_disease
infection 7 16 118 127 I-chronic_disease
( 17 18 128 129 O
e.g. 18 22 129 133 O
, 22 23 133 134 O
human 24 29 135 140 B-chronic_disease
immunodeficiency 30 46 141 157 I-chronic_disease
virus 47 52 158 163 I-chronic_disease
[ 53 54 164 165 I-chronic_disease
HIV 54 57 165 168 I-chronic_disease
] 57 58 168 169 I-chronic_disease
or 59 61 170 172 O
viral 62 67 173 178 B-chronic_disease
hepatitis 68 77 179 188 I-chronic_disease
) 77 78 188 189 O

Age 0 3 190 193 B-age
≥ 4 5 194 195 O
18 6 8 196 198 B-lower_bound
years 9 14 199 204 I-lower_bound

Castration 0 10 205 215 B-cancer
- 10 11 215 216 I-cancer
resistant 11 20 216 225 I-cancer
prostate 21 29 226 234 I-cancer
cancer 30 36 235 241 I-cancer

Eastern 0 7 242 249 B-clinical_variable
Cooperative 8 19 250 261 I-clinical_variable
Oncology 20 28 262 270 I-clinical_variable
Group 29 34 271 276 I-clinical_variable
( 35 36 277 278 I-clinical_variable
ECOG 36 40 278 282 I-clinical_variable
) 40 41 282 283 I-clinical_variable
performance 42 53 284 295 I-clinical_variable
status 54 60 296 302 I-clinical_variable
of 61 63 303 305 O
0 64 65 306 307 B-lower_bound
or 66 68 308 310 O
1 69 70 311 312 B-upper_bound

Gastrointestinal 0 16 313 329 B-chronic_disease
disorder 17 25 330 338 I-chronic_disease
affecting 26 35 339 348 O
absorption 36 46 349 359 O

Hemoglobin 0 10 360 370 B-clinical_variable
≥ 11 12 371 372 O
9g 13 15 373 375 B-lower_bound
/ 15 16 375 376 I-lower_bound
dL 16 18 376 378 I-lower_bound

Histologically 0 14 379 393 O
confirmed 15 24 394 403 O
adenocarcinoma 25 39 404 418 B-cancer
of 40 42 419 421 I-cancer
the 43 46 422 425 I-cancer
prostate 47 55 426 434 I-cancer

History 0 7 435 442 O
of 8 10 443 445 O
allergic 11 19 446 454 O
reactions 20 29 455 464 O
attributed 30 40 465 475 O
to 41 43 476 478 O
compounds 44 53 479 488 O
of 54 56 489 491 O
similar 57 64 492 499 O
chemical 65 73 500 508 O
or 74 76 509 511 O
biologic 77 85 512 520 O
composition 86 97 521 532 O
to 98 100 533 535 O
apalutamide 101 112 536 547 B-allergy_name
or 113 115 548 550 O
docetaxel 116 125 551 560 B-allergy_name

History 0 7 561 568 O
of 8 10 569 571 O
allergic 11 19 572 580 O
reactions 20 29 581 590 O
or 30 32 591 593 O
severe 33 39 594 600 O
hypersensitivity 40 56 601 617 O
reactions 57 66 618 627 O
to 67 69 628 630 O
drugs 70 75 631 636 O
formulated 76 86 637 647 O
with 87 91 648 652 O
polysorbate 92 103 653 664 B-allergy_name
80 104 106 665 667 I-allergy_name
or 107 109 668 670 O
antisense 110 119 671 680 B-allergy_name
oligonucleotides 120 136 681 697 I-allergy_name

Medications 0 11 698 709 O
known 12 17 710 715 O
to 18 20 716 718 O
lower 21 26 719 724 O
the 27 30 725 728 O
seizure 31 38 729 736 B-chronic_disease
threshold 39 48 737 746 O
must 49 53 747 751 O
be 54 56 752 754 O
discontinued 57 69 755 767 O

Pathology 0 9 768 777 O
consistent 10 20 778 788 O
with 21 25 789 793 O
majority 26 34 794 802 O
of 35 37 803 805 O
specimen 38 46 806 814 O
having 47 53 815 821 O
small 54 59 822 827 B-cancer
cell 60 64 828 832 I-cancer
carcinoma 65 74 833 842 I-cancer
of 75 77 843 845 I-cancer
the 78 81 846 849 I-cancer
prostate 82 90 850 858 I-cancer
( 91 92 859 860 O
prostate 92 100 860 868 B-cancer
cancer 101 107 869 875 I-cancer
with 108 112 876 880 O
neuroendocrine 113 127 881 895 O
features 128 136 896 904 O
is 137 139 905 907 O
acceptable 140 150 908 918 O
) 150 151 918 919 O

Peripheral 0 10 920 930 B-clinical_variable
neuropathy 11 21 931 941 I-clinical_variable
≥ 22 23 942 943 O
Grade 24 29 944 949 B-lower_bound
2 30 31 950 951 I-lower_bound

Persistent 0 10 952 962 B-clinical_variable
grade 11 16 963 968 I-clinical_variable
> 17 18 969 970 O
1 19 20 971 972 B-lower_bound
( 21 22 973 974 O
NCI 22 25 974 977 O
CTCAE 26 31 978 983 O
v4.0 32 36 984 988 O
) 36 37 988 989 O
AEs 38 41 990 993 O
due 42 45 994 997 O
to 46 48 998 1000 O
investigational 49 64 1001 1016 O
drugs 65 70 1017 1022 O
that 71 75 1023 1027 O
were 76 80 1028 1032 O
administered 81 93 1033 1045 O
more 94 98 1046 1050 O
than 99 103 1051 1055 O
14 104 106 1056 1058 B-lower_bound
days 107 111 1059 1063 I-lower_bound
before 112 118 1064 1070 O
study 119 124 1071 1076 O
enrollment 125 135 1077 1087 O

Platelet 0 8 1088 1096 B-clinical_variable
count 9 14 1097 1102 I-clinical_variable
≥ 15 16 1103 1104 O
100 17 20 1105 1108 B-lower_bound
x 21 22 1109 1110 I-lower_bound
10 23 25 1111 1113 I-lower_bound
^ 25 26 1113 1114 I-lower_bound
9 26 27 1114 1115 I-lower_bound
/ 27 28 1115 1116 I-lower_bound
L 28 29 1116 1117 I-lower_bound

Presence 0 8 1118 1126 O
of 9 11 1127 1129 O
untreated 12 21 1130 1139 O
brain 22 27 1140 1145 B-cancer
metastasis 28 38 1146 1156 I-cancer

Prior 0 5 1157 1162 B-treatment
treatment 6 15 1163 1172 I-treatment
with 16 20 1173 1177 I-treatment
enzalutamide 21 33 1178 1190 I-treatment
for 34 37 1191 1194 O
CPRC 38 42 1195 1199 B-cancer
; 42 43 1199 1200 O
non 44 47 1201 1204 O
- 47 48 1204 1205 O
CRPC 48 52 1205 1209 B-cancer
use 53 56 1210 1213 O
allowed 57 64 1214 1221 O
( 65 66 1222 1223 O
e.g. 66 70 1223 1227 O
, 70 71 1227 1228 O
neoadjuvant 72 83 1229 1240 B-treatment
, 83 84 1240 1241 O
combined 85 93 1242 1250 O
with 94 98 1251 1255 O
radiation 99 108 1256 1265 B-treatment
for 109 112 1266 1269 O
localized 113 122 1270 1279 O
disease 123 130 1280 1287 O
and 131 134 1288 1291 O
did 135 138 1292 1295 O
n't 138 141 1295 1298 O
progress 142 150 1299 1307 O
while 151 156 1308 1313 O
on 157 159 1314 1316 O
it 160 162 1317 1319 O
in 163 165 1320 1322 O
those 166 171 1323 1328 O
settings 172 180 1329 1337 O
) 180 181 1337 1338 O

Prostate 0 8 1339 1347 B-cancer
cancer 9 15 1348 1354 I-cancer
progression 16 27 1355 1366 O
on 28 30 1367 1369 O
or 31 33 1370 1372 O
since 34 39 1373 1378 O
last 40 44 1379 1383 O
treatment 45 54 1384 1393 O
as 55 57 1394 1396 O
documented 58 68 1397 1407 O
by 69 71 1408 1410 O
PSA 72 75 1411 1414 O
rise 76 80 1415 1419 O
or 81 83 1420 1422 O
bone 84 88 1423 1427 O
progression 89 100 1428 1439 O
according 101 110 1440 1449 O
to 111 113 1450 1452 O
PCWG2 114 119 1453 1458 O
or 120 122 1459 1461 O
soft 123 127 1462 1466 O
tissue 128 134 1467 1473 O
radiographic 135 147 1474 1486 O
progression 148 159 1487 1498 O
according 160 169 1499 1508 O
to 170 172 1509 1511 O
RECIST 173 179 1512 1518 O
criteria 180 188 1519 1527 O
Version 189 196 1528 1535 O
1.1 197 200 1536 1539 O

Psychiatric 0 11 1540 1551 B-chronic_disease
illness 12 19 1552 1559 I-chronic_disease
/ 19 20 1559 1560 O
social 20 26 1560 1566 B-chronic_disease
situations 27 37 1567 1577 I-chronic_disease
that 38 42 1578 1582 O
would 43 48 1583 1588 O
limit 49 54 1589 1594 O
compliance 55 65 1595 1605 O
with 66 70 1606 1610 O
study 71 76 1611 1616 O
requirements 77 89 1617 1629 O

Seizure 0 7 1630 1637 B-chronic_disease
or 8 10 1638 1640 O
known 11 16 1641 1646 O
condition 17 26 1647 1656 O
that 27 31 1657 1661 O
may 32 35 1662 1665 O
pre 36 39 1666 1669 O
- 39 40 1669 1670 O
dispose 40 47 1670 1677 O
to 48 50 1678 1680 O
seizure 51 58 1681 1688 B-chronic_disease
( 59 60 1689 1690 O
including 60 69 1690 1699 O
but 70 73 1700 1703 O
not 74 77 1704 1707 O
limited 78 85 1708 1715 O
to 86 88 1716 1718 O
prior 89 94 1719 1724 O
stroke 95 101 1725 1731 B-chronic_disease
, 101 102 1731 1732 O
transient 103 112 1733 1742 B-chronic_disease
ischemic 113 121 1743 1751 I-chronic_disease
attack 122 128 1752 1758 I-chronic_disease
within 129 135 1759 1765 O
1 136 137 1766 1767 B-upper_bound
year 138 142 1768 1772 I-upper_bound
prior 143 148 1773 1778 I-upper_bound
to 149 151 1779 1781 O
randomization 152 165 1782 1795 O
, 165 166 1795 1796 O
brain 167 172 1797 1802 B-chronic_disease
arteriovenous 173 186 1803 1816 I-chronic_disease
malformation 187 199 1817 1829 I-chronic_disease
; 199 200 1829 1830 O
or 201 203 1831 1833 O
intracranial 204 216 1834 1846 B-cancer
masses 217 223 1847 1853 I-cancer
such 224 228 1854 1858 O
as 229 231 1859 1861 O
schwannomas 232 243 1862 1873 B-cancer
and 244 247 1874 1877 O
meningiomas 248 259 1878 1889 B-cancer
that 260 264 1890 1894 O
are 265 268 1895 1898 O
causing 269 276 1899 1906 O
edema 277 282 1907 1912 B-chronic_disease
or 283 285 1913 1915 O
mass 286 290 1916 1920 O
effect 291 297 1921 1927 O
) 297 298 1927 1928 O

Serum 0 5 1929 1934 B-clinical_variable
albumin 6 13 1935 1942 I-clinical_variable
≥ 14 15 1943 1944 O
3.0 16 19 1945 1948 B-lower_bound
g 20 21 1949 1950 I-lower_bound
/ 21 22 1950 1951 I-lower_bound
dL 22 24 1951 1953 I-lower_bound

The 0 3 1954 1957 O
effects 4 11 1958 1965 O
of 12 14 1966 1968 O
apalutamide 15 26 1969 1980 B-treatment
and 27 30 1981 1984 O
docetaxel 31 40 1985 1994 B-treatment
on 41 43 1995 1997 O
the 44 47 1998 2001 O
developing 48 58 2002 2012 O
human 59 64 2013 2018 O
fetus 65 70 2019 2024 O
are 71 74 2025 2028 O
unknown 75 82 2029 2036 O

They 0 4 2037 2041 O
must 5 9 2042 2046 O
also 10 14 2047 2051 O
agree 15 20 2052 2057 O
not 21 24 2058 2061 O
to 25 27 2062 2064 O
donate 28 34 2065 2071 O
sperm 35 40 2072 2077 O
during 41 47 2078 2084 O
the 48 51 2085 2088 O
study 52 57 2089 2094 O
and 58 61 2095 2098 O
for 62 65 2099 2102 O
3 66 67 2103 2104 B-upper_bound
months 68 74 2105 2111 I-upper_bound
after 75 80 2112 2117 O
receiving 81 90 2118 2127 O
the 91 94 2128 2131 O
last 95 99 2132 2136 O
dose 100 104 2137 2141 O
of 105 107 2142 2144 O
study 108 113 2145 2150 O
drug 114 118 2151 2155 O

Total 0 5 2156 2161 O
bilirubin 6 15 2162 2171 B-clinical_variable
≤ 16 17 2172 2173 O
upper 18 23 2174 2179 O
limit 24 29 2180 2185 O
of 30 32 2186 2188 O
normal 33 39 2189 2195 O

Treatment 0 9 2196 2205 B-treatment
with 10 14 2206 2210 O
abiraterone 15 26 2211 2222 B-treatment
acetate 27 34 2223 2230 I-treatment
for 35 38 2231 2234 O
CRPC 39 43 2235 2239 B-chronic_disease
in 44 46 2240 2242 O
the 47 50 2243 2246 O
past 51 55 2247 2251 O
is 56 58 2252 2254 O
required 59 67 2255 2263 O

arterial 0 8 2264 2272 B-chronic_disease
or 9 11 2273 2275 I-chronic_disease
venous 12 18 2276 2282 I-chronic_disease
thromboembolic 19 33 2283 2297 I-chronic_disease
events 34 40 2298 2304 I-chronic_disease
( 41 42 2305 2306 O
e.g. 42 46 2306 2310 O
, 46 47 2310 2311 O
pulmonary 48 57 2312 2321 B-chronic_disease
embolism 58 66 2322 2330 I-chronic_disease
) 66 67 2330 2331 O

clinically 0 10 2332 2342 O
significant 11 22 2343 2354 O
ventricular 23 34 2355 2366 B-chronic_disease
arrhythmias 35 46 2367 2378 I-chronic_disease
, 46 47 2378 2379 O
significant 48 59 2380 2391 O
vascular 60 68 2392 2400 B-chronic_disease
disease 69 76 2401 2408 I-chronic_disease
( 77 78 2409 2410 O
e.g. 78 82 2410 2414 O
aortic 83 89 2415 2421 B-chronic_disease
aneurysm 90 98 2422 2430 I-chronic_disease
, 98 99 2430 2431 O
aortic 100 106 2432 2438 B-chronic_disease
dissection 107 117 2439 2449 I-chronic_disease
) 117 118 2449 2450 O

men 0 3 2451 2454 B-gender
must 4 8 2455 2459 O
agree 9 14 2460 2465 B-contraception_consent
to 15 17 2466 2468 I-contraception_consent
use 18 21 2469 2472 I-contraception_consent
adequate 22 30 2473 2481 I-contraception_consent
contraception 31 44 2482 2495 I-contraception_consent

no 0 2 2496 2498 O
transfusions 3 15 2499 2511 B-treatment
and 16 19 2512 2515 O
erythropoietin 20 34 2516 2530 B-treatment
supplementation 35 50 2531 2546 I-treatment
permitted 51 60 2547 2556 O
within 61 67 2557 2563 O
the 68 71 2564 2567 O
last 72 76 2568 2572 B-upper_bound
3 77 78 2573 2574 I-upper_bound
months 79 85 2575 2581 I-upper_bound

other 0 5 2582 2587 O
medical 6 13 2588 2595 B-chronic_disease
condition 14 23 2596 2605 I-chronic_disease
that 24 28 2606 2610 O
would 29 34 2611 2616 O
make 35 39 2617 2621 O
prednisone 40 50 2622 2632 B-treatment
/ 50 51 2632 2633 O
prednisolone 51 63 2633 2645 B-treatment
( 64 65 2646 2647 O
corticosteroid 65 79 2647 2661 B-treatment
) 79 80 2661 2662 O
use 81 84 2663 2666 O
contraindicated 85 100 2667 2682 O

recent 0 6 2683 2689 O
( 7 8 2690 2691 O
within 8 14 2691 2697 O
4 15 16 2698 2699 B-upper_bound
weeks 17 22 2700 2705 I-upper_bound
of 23 25 2706 2708 O
the 26 29 2709 2712 O
first 30 35 2713 2718 O
dose 36 40 2719 2723 O
of 41 43 2724 2726 O
this 44 48 2727 2731 O
study 49 54 2732 2737 O
) 54 55 2737 2738 O

symptomatic 0 11 2739 2750 O
peripheral 12 22 2751 2761 B-chronic_disease
vascular 23 31 2762 2770 I-chronic_disease
disease 32 39 2771 2778 I-chronic_disease
within 40 46 2779 2785 O
6 47 48 2786 2787 B-upper_bound
months 49 55 2788 2794 I-upper_bound
prior 56 61 2795 2800 I-upper_bound
to 62 64 2801 2803 O
randomization 65 78 2804 2817 O

